Miofree (Atropine Sulfate)

Atropine sulfate, the active ingredient in Miofree, is an anticholinergic (muscarinic antagonist) presented as a sterile ophthalmic preparation for ocular administration. It blocks parasympathetic input to the iris sphincter and ciliary muscle, producing reliable pupil dilation and cycloplegia for diagnostic and therapeutic purposes in diverse patient populations.

GNH USA supplies Miofree as a licensed, GDP‑compliant international pharmaceutical supplier, delivering the product to hospitals, pharmacies and clinics across global markets, with a focus on EU‑origin quality standards. The company also supports regulatory compliance for each region it serves.

Atropine sulfate is employed in ophthalmology to achieve targeted muscarinic blockade for several clinical purposes.

- Pupil dilation for ophthalmic examination: enables thorough retinal and optic nerve assessment by widening the pupil. - Cycloplegia for diagnostic or therapeutic purposes: temporarily paralyzes accommodation to facilitate accurate refraction and treat certain inflammatory conditions. - Adjunct in treatment of anterior uveitis: reduces intra‑ocular inflammation and pain by limiting parasympathetic‑mediated aqueous humor dynamics. - Management of amblyopia (occlusion therapy): used to blur the better‑seeing eye, encouraging use of the weaker eye during therapy.

Ocular administration of atropine sulfate may be associated with a range of adverse reactions.

Common Side Effects: - Transient ocular burning or stinging sensation upon instillation. - Temporary blurred vision and increased light sensitivity (photophobia). - Mild conjunctival redness or hyperemia that resolves within hours. - Dry eye sensation due to reduced tear secretion.

Serious or Rare Side Effects: - Acute angle‑closure glaucoma, a vision‑threatening emergency. - Persistent mydriasis leading to prolonged visual disturbance. - Severe allergic reaction such as angioedema or anaphylaxis requiring immediate medical attention. - Systemic anticholinergic effects (e.g., tachycardia, dry mouth) rarely observed.

When using atropine sulfate ophthalmic preparations, several precautions should be observed to ensure safety and efficacy. - Assess intra‑ocular pressure before use: avoid in patients with narrow‑angle glaucoma risk. - Verify allergy history: contraindicated in individuals with known hypersensitivity to atropine or excipients. - Use appropriate dosage: follow prescriber instructions to minimize prolonged mydriasis. - Monitor pediatric patients closely: children may be more susceptible to systemic absorption. - Avoid contact lens wear immediately after instillation: lenses can trap the drug and increase exposure. - Store at ambient temperature: keep in original container, protect from light and moisture.

Atropine sulfate may interact with other agents that influence cholinergic pathways or ocular physiology.

Major Interactions (Avoid): - Systemic anticholinergic drugs (e.g., antihistamines, tricyclic antidepressants): additive anticholinergic load may increase systemic side effects. - Topical ocular sympathomimetics (e.g., phenylephrine): combined use can cause excessive pupil dilation and raise intra‑ocular pressure.

Moderate Interactions (Monitor Closely): - Carbonic anhydrase inhibitors (e.g., acetazolamide): may affect intra‑ocular pressure control when used together. - Non‑steroidal anti‑inflammatory eye drops: monitor for altered corneal healing. - Beta‑blocker eye drops: observe for potential changes in systemic cardiovascular effects.